A Modified Nucleoside 6-Thio-2′-Deoxyguanosine Exhibits Antitumor Activity in Gliomas

Purpose: To investigate the therapeutic role of a novel telomere-directed inhibitor, 6-thio-2′-deoxyguanosine (THIO) in gliomas both in vitro and in vivo. Experimental Design: A panel of human and mouse glioma cell lines was used to test therapeutic efficacy of THIO using cell viability assays, flow cytometric analyses, and immunofluorescence. Integrated analyses of RNA sequencing and reverse-phase protein array data revealed the potential antitumor mechanisms of THIO. Four patient-derived xenografts (PDX), two patient-derived organoids (PDO), and two xenografts of human glioma cell lines were used to further investigate the therapeutic efficacy of THIO. Results: THIO was effective in the majority of human and mouse glioma cell lines with no obvious toxicity against normal astrocytes. THIO as a monotherapy demonstrated efficacy in three glioma cell lines that had acquired resistance to temozolomide. In addition, THIO showed efficacy in four human glioma cell lines grown as neurospheres by inducing apoptotic cell death. Mechanistically, THIO induced telomeric DNA damage not only in glioma cell lines but also in PDX tumor specimens. Integrated computational analyses of transcriptomic and proteomic data indicated that THIO significantly inhibited cell invasion, stem cell, and proliferation pathways while triggering DNA damage and apoptosis. Importantly, THIO significantly decreased tumor proliferation in two PDO models and reduced the tumor size of a glioblastoma xenograft and a PDX model. Conclusions: The current study established the therapeutic role of THIO in primary and recurrent gliomas and revealed the acute induction of telomeric DNA damage as a primary antitumor mechanism of THIO in gliomas.

[1]  J. Shay,et al.  Telomere Stress Potentiates STING-Dependent Anti-tumor Immunity. , 2020, Cancer cell.

[2]  Ping Wang,et al.  BIBR1532, a selective telomerase inhibitor, enhances radiosensitivity of non-small cell lung cancer through increasing telomere dysfunction and ATM/CHK1 inhibition. , 2019, International journal of radiation oncology, biology, physics.

[3]  Gao Zhang,et al.  In perspective: An update on telomere targeting in cancer , 2019, Molecular carcinogenesis.

[4]  Jun S. Song,et al.  Disruption of the β1L Isoform of GABP Reverses Glioblastoma Replicative Immortality in a TERT Promoter Mutation-Dependent Manner. , 2018, Cancer cell.

[5]  Lani F. Wu,et al.  Telomerase-Mediated Strategy for Overcoming Non–Small Cell Lung Cancer Targeted Therapy and Chemotherapy Resistance , 2018, Neoplasia.

[6]  P. Lowenstein,et al.  Mutant ATRX: uncovering a new therapeutic target for glioma , 2018, Expert opinion on therapeutic targets.

[7]  L. J. Lee,et al.  Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma. , 2018, Cancer research.

[8]  J. Shay,et al.  Induced Telomere Damage to Treat Telomerase Expressing Therapy-Resistant Pediatric Brain Tumors , 2018, Molecular Cancer Therapeutics.

[9]  G. Mills,et al.  Induction of Telomere Dysfunction Prolongs Disease Control of Therapy-Resistant Melanoma , 2018, Clinical Cancer Research.

[10]  Songlin Liu,et al.  Inhibition of Rb and mTOR signaling associates with synergistic anticancer effect of palbociclib and erlotinib in glioblastoma cells , 2018, Investigational New Drugs.

[11]  A. Elia,et al.  New Directions in the Treatment of Glioblastoma , 2018, Seminars in Neurology.

[12]  Xin Hu,et al.  Systematic analysis of telomere length and somatic alterations in 31 cancer types , 2017, Nature Genetics.

[13]  I. Yeh.  Faculty Opinions recommendation of Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer. , 2016 .

[14]  J. Shay,et al.  A novel telomerase substrate precursor rapidly induces telomere dysfunction in telomerase positive cancer cells but not telomerase silent normal cells , 2015, Oncoscience.

[15]  Chibo Hong,et al.  The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer , 2015, Science.

[16]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[17]  Paul Theodor Pyl,et al.  HTSeq – A Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[18]  I. Pastan,et al.  Recombinant anti‐podoplanin (NZ‐1) immunotoxin for the treatment of malignant brain tumors , 2013, International journal of cancer.

[19]  Gary L. Gallia,et al.  TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal , 2013, Proceedings of the National Academy of Sciences.

[20]  Roland L. Dunbrack,et al.  A Modified HSP70 Inhibitor Shows Broad Activity as an Anticancer Agent , 2013, Molecular Cancer Research.

[21]  M. Lindström,et al.  PDGF and PDGF receptors in glioma , 2012, Upsala journal of medical sciences.

[22]  J. Sarkaria,et al.  Establishment, Maintenance, and In Vitro and In Vivo Applications of Primary Human Glioblastoma Multiforme (GBM) Xenograft Models for Translational Biology Studies and Drug Discovery , 2011, Current protocols in pharmacology.

[23]  M. Dewhirst,et al.  Cellular redox modulator, ortho Mn(III) meso-tetrakis(N-n-hexylpyridinium-2-yl)porphyrin, MnTnHex-2-PyP(5+) in the treatment of brain tumors. , 2011, Anti-cancer agents in medicinal chemistry.

[24]  Gonçalo R. Abecasis,et al.  The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..

[25]  B. Rýchly,et al.  [The 2007 World Health Organisation classification of tumours of the central nervous system, comparison with 2000 classification]. , 2008, Ceskoslovenska patologie.

[26]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  R. Cawthon.  Telomere measurement by quantitative PCR. , 2002, Nucleic acids research.

[28]  S. Keir,et al.  Therapeutic activity of 7-[(2-trimethylsilyl)ethyl)]-20 (S)-camptothecin against central nervous system tumor-derived xenografts in athymic mice , 2001, Cancer Chemotherapy and Pharmacology.

[29]  L. Muhlbaier,et al.  Experimental chemotherapy of human medulloblastoma cell lines and transplantable xenografts with bifunctional alkylating agents. , 1988, Cancer Research.

[30]  Kahkashan Perveen,et al.  Glioblastoma Multiforme: A Review of its Epidemiology and Pathogenesis through Clinical Presentation and Treatment , 2017, Asian Pacific journal of cancer prevention : APJCP.

[31]  J. Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. , 2016, Neuro-oncology.

[32]  J. Shay,et al.  Induction of telomere dysfunction mediated by the telomerase substrate precursor 6-thio-2'-deoxyguanosine. , 2015, Cancer discovery.

[33]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..

[34]  S. Keir,et al.  Mibefradil, a novel therapy for glioblastoma multiforme: cell cycle synchronization and interlaced therapy in a murine model , 2012, Journal of Neuro-Oncology.

[35]  S. Keir,et al.  Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts , 2004, Cancer Chemotherapy and Pharmacology.

[36]  J. Shay,et al.  Telomerase activity in human cancer. , 1996, Current opinion in oncology.